Clinical Trial Update: Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating intradermal rHuPH20 versus placebo in nickel allergic contact dermatitis completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatitis Allergic Contact
• Nickel Allergy Contact Dermatitis

Drugs mentioned

• rHuPH20 (recombinant human hyaluronidase PH20)

Snippet

Sponsor: Halozyme Therapeutics | Conditions: Dermatitis, Allergic Contact | Phase 2 | Status: COMPLETED | Results posted: 2021-12-17